Science
Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo – Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies w
DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a new paper published online in Nature Communications that reportspreclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA in vivo.
The study, Mitochondrial targeted meganuclease as a platform to eliminate…
-
General7 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News17 hours agoRainbow Beach surfer’s untold 7/7 story
-
General24 hours agoParis opens River Seine for public swimming for first time since 1923
-
General22 hours agoWest Indies vs Australia live: Second Test, day three from Grenada